HE4 as a biomarker for diagnosis of lung cancer: A meta-analysis

BACKGROUND: The aim of our study was to assess the value of serum human epididymis protein 4 (HE4) to diagnose lung cancer and provide reliable scientific conclusions to guide clinical practice. METHODS: A systematic search of the PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastr...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yong-Peng, Li, Li-Xian, Tang, Jia-Xi, Yi, Lin, Zhao, Yi, Zhang, Hai-Wei, Wu, Zhi-Juan, Lei, Hai-Ke, Yu, Hui-Qing, Nian, Wei-Qi, Gan, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775374/
https://www.ncbi.nlm.nih.gov/pubmed/31574828
http://dx.doi.org/10.1097/MD.0000000000017198
_version_ 1783456233719595008
author He, Yong-Peng
Li, Li-Xian
Tang, Jia-Xi
Yi, Lin
Zhao, Yi
Zhang, Hai-Wei
Wu, Zhi-Juan
Lei, Hai-Ke
Yu, Hui-Qing
Nian, Wei-Qi
Gan, Lin
author_facet He, Yong-Peng
Li, Li-Xian
Tang, Jia-Xi
Yi, Lin
Zhao, Yi
Zhang, Hai-Wei
Wu, Zhi-Juan
Lei, Hai-Ke
Yu, Hui-Qing
Nian, Wei-Qi
Gan, Lin
author_sort He, Yong-Peng
collection PubMed
description BACKGROUND: The aim of our study was to assess the value of serum human epididymis protein 4 (HE4) to diagnose lung cancer and provide reliable scientific conclusions to guide clinical practice. METHODS: A systematic search of the PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature, and WANFANG databases was conducted to identify all studies examining serum HE4 in the diagnosis of lung cancer published up to June, 2017. The Quality Assessment of Diagnostic Accuracy Studies tool was used to evaluate the methodological quality of each trial. The meta-analysis was performed using STATA software and Review Manager 5.3. RESULTS: There were 21 studies involving 1883 cases and 1696 controls included in our meta-analysis. The pooled sensitivity and specificity of HE4 for diagnosing lung cancer were 0.73 (95% confidence interval [CI] 0.68–0.78) and 0.86 (95% CI 0.81–0.91), respectively. The positive likelihood ratio and negative likelihood ratio were 5.4 (95% CI 3.8–7.5) and 0.31 (95% CI 0.26–0.37), respectively. The diagnostic odds ratio was 17 (95% CI 12–26). The area under the curve of the summary receiver-operating characteristic curve was 0.86 (95% CI 0.83–0.89). Race, assay method, type of cancer, sample size, and publication date might be sources of heterogeneity in our meta-analysis. Subgroup analyses showed that the sensitivity in Caucasians was higher than that in Asians (0.81, 95% CI 0.71–0.91; and 0.71, 95% CI 0.66–0.77, respectively), but the specificity in Asians was better than that in Caucasians (0.87, 95% CI 0.81–0.92; and 0.85, 95% CI 0.73–0.97, respectively). The chemiluminescent microparticle immunoassay had the highest sensitivity, with 0.79 (95% CI 0.73–0.97), and the enzyme-linked immunosorbent assay had the highest specificity, with 0.87 (95% CI 0.79–0.94). HE4 had high diagnostic efficacy when screening for small cell lung cancer with the highest specificity (0.90, 95% CI 0.77–1.00). CONCLUSIONS: HE4 is a relatively promising and effective biomarker for the diagnosis of lung cancer. Furthermore, given the limitations of our study, additional large-scale and well-designed studies are needed in the future.
format Online
Article
Text
id pubmed-6775374
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-67753742019-10-07 HE4 as a biomarker for diagnosis of lung cancer: A meta-analysis He, Yong-Peng Li, Li-Xian Tang, Jia-Xi Yi, Lin Zhao, Yi Zhang, Hai-Wei Wu, Zhi-Juan Lei, Hai-Ke Yu, Hui-Qing Nian, Wei-Qi Gan, Lin Medicine (Baltimore) 4100 BACKGROUND: The aim of our study was to assess the value of serum human epididymis protein 4 (HE4) to diagnose lung cancer and provide reliable scientific conclusions to guide clinical practice. METHODS: A systematic search of the PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature, and WANFANG databases was conducted to identify all studies examining serum HE4 in the diagnosis of lung cancer published up to June, 2017. The Quality Assessment of Diagnostic Accuracy Studies tool was used to evaluate the methodological quality of each trial. The meta-analysis was performed using STATA software and Review Manager 5.3. RESULTS: There were 21 studies involving 1883 cases and 1696 controls included in our meta-analysis. The pooled sensitivity and specificity of HE4 for diagnosing lung cancer were 0.73 (95% confidence interval [CI] 0.68–0.78) and 0.86 (95% CI 0.81–0.91), respectively. The positive likelihood ratio and negative likelihood ratio were 5.4 (95% CI 3.8–7.5) and 0.31 (95% CI 0.26–0.37), respectively. The diagnostic odds ratio was 17 (95% CI 12–26). The area under the curve of the summary receiver-operating characteristic curve was 0.86 (95% CI 0.83–0.89). Race, assay method, type of cancer, sample size, and publication date might be sources of heterogeneity in our meta-analysis. Subgroup analyses showed that the sensitivity in Caucasians was higher than that in Asians (0.81, 95% CI 0.71–0.91; and 0.71, 95% CI 0.66–0.77, respectively), but the specificity in Asians was better than that in Caucasians (0.87, 95% CI 0.81–0.92; and 0.85, 95% CI 0.73–0.97, respectively). The chemiluminescent microparticle immunoassay had the highest sensitivity, with 0.79 (95% CI 0.73–0.97), and the enzyme-linked immunosorbent assay had the highest specificity, with 0.87 (95% CI 0.79–0.94). HE4 had high diagnostic efficacy when screening for small cell lung cancer with the highest specificity (0.90, 95% CI 0.77–1.00). CONCLUSIONS: HE4 is a relatively promising and effective biomarker for the diagnosis of lung cancer. Furthermore, given the limitations of our study, additional large-scale and well-designed studies are needed in the future. Wolters Kluwer Health 2019-09-27 /pmc/articles/PMC6775374/ /pubmed/31574828 http://dx.doi.org/10.1097/MD.0000000000017198 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 4100
He, Yong-Peng
Li, Li-Xian
Tang, Jia-Xi
Yi, Lin
Zhao, Yi
Zhang, Hai-Wei
Wu, Zhi-Juan
Lei, Hai-Ke
Yu, Hui-Qing
Nian, Wei-Qi
Gan, Lin
HE4 as a biomarker for diagnosis of lung cancer: A meta-analysis
title HE4 as a biomarker for diagnosis of lung cancer: A meta-analysis
title_full HE4 as a biomarker for diagnosis of lung cancer: A meta-analysis
title_fullStr HE4 as a biomarker for diagnosis of lung cancer: A meta-analysis
title_full_unstemmed HE4 as a biomarker for diagnosis of lung cancer: A meta-analysis
title_short HE4 as a biomarker for diagnosis of lung cancer: A meta-analysis
title_sort he4 as a biomarker for diagnosis of lung cancer: a meta-analysis
topic 4100
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775374/
https://www.ncbi.nlm.nih.gov/pubmed/31574828
http://dx.doi.org/10.1097/MD.0000000000017198
work_keys_str_mv AT heyongpeng he4asabiomarkerfordiagnosisoflungcancerametaanalysis
AT lilixian he4asabiomarkerfordiagnosisoflungcancerametaanalysis
AT tangjiaxi he4asabiomarkerfordiagnosisoflungcancerametaanalysis
AT yilin he4asabiomarkerfordiagnosisoflungcancerametaanalysis
AT zhaoyi he4asabiomarkerfordiagnosisoflungcancerametaanalysis
AT zhanghaiwei he4asabiomarkerfordiagnosisoflungcancerametaanalysis
AT wuzhijuan he4asabiomarkerfordiagnosisoflungcancerametaanalysis
AT leihaike he4asabiomarkerfordiagnosisoflungcancerametaanalysis
AT yuhuiqing he4asabiomarkerfordiagnosisoflungcancerametaanalysis
AT nianweiqi he4asabiomarkerfordiagnosisoflungcancerametaanalysis
AT ganlin he4asabiomarkerfordiagnosisoflungcancerametaanalysis